Rituximab and Ocrelizumab in Serum With Multiple Sclerosis
Recruiting
Observational Study
Relapsing Remitting Multiple Sclerosis
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 60
- Sex
- Any
- Study type
- Observational
- Participants needed
- 60 (estimated)
- Sponsor
- Haukeland University Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
ROS-MS is a clinical pharmacological substudy to the OVERLORD-MS study (NCT04578639), designed to examine the possibilities of personalized treatment with rituximab and ocrelizumab in patients with relapsing-remitting multiple sclerosis.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Included in OVERLORD-MS (NCT04578639)
* Willing to attend laboratory for blood sample collection at scheduled time points
Exclusion criteria:
\* Not willing to attend laboratory for blood sample collection at scheduled time points
Contacts